Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
Fish and Richardson
Merck
McKinsey
Colorcon
Baxter
Covington
Queensland Health
QuintilesIMS

Generated: October 17, 2017

DrugPatentWatch Database Preview

OTEZLA Drug Profile

« Back to Dashboard

What is the patent landscape for Otezla, and what generic Otezla alternatives are available?

Otezla is a drug marketed by Celgene Corp and is included in one NDA. There are nine patents protecting this drug.

This drug has eighty-eight patent family members in twenty-two countries.

The generic ingredient in OTEZLA is apremilast. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.

Summary for Tradename: OTEZLA

US Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list35
Clinical Trials: see list21
Patent Applications: see list63
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OTEZLA at DailyMed

Pharmacology for Tradename: OTEZLA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-002Mar 21, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-001Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-002Mar 21, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-003Mar 21, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-001Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Celgene Corp
OTEZLA
apremilast
TABLET;ORAL205437-001Mar 21, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OTEZLA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,303Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione► Subscribe
6,011,050 Substituted phenethylsulfones and method of reducing TNF.alpha. levels► Subscribe
9,283,207Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
9,433,606Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof► Subscribe
9,724,330Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
7,358,272Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione► Subscribe
7,507,759Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-- 4-acetylaminoisoindoline-1,3,-dione► Subscribe
8,093,283Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisi- noline-1,3-dione, compositions thereof, and uses thereof► Subscribe
7,276,529Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione► Subscribe
8,629,173Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OTEZLA

Country Document Number Estimated Expiration
Portugal2420490► Subscribe
European Patent Office2223687► Subscribe
Japan2015013893► Subscribe
Germany69934708► Subscribe
SloveniaEP1485087► Subscribe
Australia1447200► Subscribe
Denmark2223687► Subscribe
European Patent Office1126839► Subscribe
Australia2003224729► Subscribe
World Intellectual Property Organization (WIPO)0025777► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
McKinsey
Boehringer Ingelheim
Covington
Merck
Healthtrust
Chinese Patent Office
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot